Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study

Published:2020-09-06 Issue:12 Volume:27 Page:1095-1100
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Tanaka Toshikazu¹,Hatakeyama Shingo²,Numakura Kazuyuki³,Kido Koichi¹,Noro Daisuke⁴,Oikawa Masaaki⁵,Hosogoe Shogo⁶,Tokui Noriko⁷,Yamamoto Hayato¹,Narita Shintaro³,Ito Hiroyuki⁸,Yoneyama Takahiro⁹,Hashimoto Yasuhiro¹,Kawaguchi Toshiaki¹⁰,Habuchi Tomonori³,Ohyama Chikara¹²⁹

Affiliation:

1. Department of Urology Hirosaki University Graduate School of Medicine HirosakiJapan

2. Department of Advanced Blood Purification Therapy Hirosaki University Graduate School of Medicine HirosakiJapan

3. Department of Urology Akita University Graduate School of Medicine AkitaJapan

4. Department of Urology Mutsu General Hospital MutsuJapan

5. Department of Urology Hakodate Municipal Hospital HakodateJapan

6. Department of Urology Aomori City Hospital AomoriJapan

7. Department of Urology Odate Municipal Hospital OdateJapan

8. Department of Urology Aomori Rosai Hospital HachinoheJapan

9. Department of Advanced Transplant Regenerative Medicine Hirosaki University Graduate School of Medicine HirosakiJapan

10. Department of Urology Aomori Prefectural Central Hospital Aomori Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14363

Reference30 articles.

1. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

2. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial

3. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan

4. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma

5. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up;Japanese Journal of Clinical Oncology;2024-01-20

2. All-cause and immune checkpoint inhibitor–associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality;Clinical Kidney Journal;2023-11-28

3. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study;Clinical Genitourinary Cancer;2023-10

4. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis;International Journal of Clinical Oncology;2023-09-02

5. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: Immortal time bias-corrected analysis.;2023-05-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3